Citius Pharmaceuticals (CTXR) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Citius Pharmaceuticals (CTXR) has outperformed Pluri (PLUR) over the past year, losing 62.0% versus a loss of 75.5%. Over five years, PLUR leads with a -95.2% price change compared with -99.1% for CTXR. Citius Pharmaceuticals is the larger company by market cap ($13.4 million vs $12.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTXR | PLUR |
|---|---|---|
| Share price | $0.4887 | $1.00 |
| Market cap | $13.42M | $12.61M |
| 1-day change | -2.47% | -3.85% |
| YTD return | -37.10% | -66.56% |
| 1-year return | -61.97% | -75.49% |
| 5-year return | -99.06% | -95.23% |
| EPS (TTM) | $-1.75 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.19 | $4.87 |
| 52-week low | $0.469 | $0.85 |
| Distance from 52-week high | -77.68% | -79.47% |
| Analyst consensus | none | — |
| Avg. price target upside | +718.50% | — |
| Average volume | 527.79K | 24.97K |
| Shares outstanding | 27.45M | 12.61M |
| Employees | 23 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTXR has outperformed PLUR by 13.5 percentage points over the past year.
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Healthcare · Biotechnology · 23 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
CTXR vs PLUR FAQ
Which is bigger, Citius Pharmaceuticals or Pluri?
Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.42M compared with $12.61M for Pluri (PLUR).
Which stock has performed better over the past year, CTXR or PLUR?
CTXR returned -61.97% over the past 12 months, compared with -75.49% for PLUR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Pharmaceuticals and Pluri in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.